Responses
Regular and young investigator award abstracts
Clinical trials in progress
395 A first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, in patients with advanced cancer and resistance to PD-(L)1 therapy
Compose a Response to This Article
Other responses
No responses have been published for this article.